StockNews.AI
ALKS
StockNews.AI
8 days

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

1. Alkermes will host a Q4 2024 earnings call on Feb 12, 2025. 2. Management will update on 2025 financial expectations and company updates. 3. Access will be available via the company's website and dial-in for callers. 4. Alkermes specializes in treatments for addiction, schizophrenia, and more. 5. The company has a pipeline for neurological disorders in development.

Earnings
-0.25%Current Return
VS
+0.34%S&P 500
$31.4702/05 04:03 PM EDTEvent Start
$31.3902/06 10:51 PM EDTLatest Updated
4 mins saved
Full Article

FAQ

Why Neutral?

The earnings call may provide insights, but expectations are generally priced in.

How important is it?

The earnings call is important, but lack of groundbreaking news may limit impact.

Why Short Term?

Immediate attention around the earnings call could affect price temporarily.

Related Companies

ALKS
, /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com. Alkermes Contact: Jamie ConstantineInvestor Relations+1 781 873 2402 SOURCE Alkermes plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News